New drug duo targets Hard-to-Treat prostate cancer in early trial
NCT ID NCT06616155
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 26 times
Summary
This early-phase study tests whether adding ruxolitinib to standard enzalutamide is safe and effective for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 20 participants will receive the combination to find the best dose and check for tumor shrinkage or PSA reduction. The goal is to control the disease, not cure it, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karmanos Cancer Institute
NOT_YET_RECRUITINGDetroit, Michigan, 48201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rush University
NOT_YET_RECRUITINGChicago, Illinois, 60612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Michigan Comprehensive Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.